Introduction {#Sec1}
============

Non-communicable diseases (NCDs), such as coronary heart disease (CHD), stroke, chronic obstructive pulmonary disease (COPD), cancer, type 2 diabetes and chronic kidney disease (CKD) currently constitute the number one cause of morbidity and mortality worldwide, claiming 36 million lives each year (accounting for 63 % of all adult deaths) \[[@CR1]\]. Infectious disease prevention and control, economic growth, improvements in medical and scientific knowledge, and health and social systems development have all contributed to increased life expectancy, improved quality of life and increased likelihood of living to age 60 years and beyond. While these are notable achievements, together with lifestyle-related shifts, these epidemiological and socio-demographic changes also mean that the burden of NCDs will grow \[[@CR2]\].

Productivity is a measure of the efficiency of a person, business or country in converting inputs into useful outputs. The productive age span of a person is from adulthood to retirement and ranges from 18 years to around 65 years of age depending on, amongst other things, profession and country. The measurement of productivity greatly relies on the output and the economic or social system context. The focus in this report is macro-economic productivity loss in the productive age range due to NCDs. Key macro-economic measures related to the labor market include: (un-) employment, (loss in) hours worked (including full or part-time work status change), presenteeism (defined as impaired performance while at work), absenteeism, disability adjusted life years (DALYs) and productivity costs/losses. Key macro-economic outcomes are reduction in the able workforce, NCD-related health and welfare expenditure and loss of income earned by the productive workforce. While both the burden of NCDs and the socio-economic contexts vary greatly, the impact of the former on macro-economic outcomes across the global regions remains unclear.

We aimed to systematically identify and summarize the literature investigating the impact of six NCDs (CHD, stroke, COPD cancer, type 2 diabetes and CKD) on macro-economic productivity and to determine directions for future research.

Methods {#Sec2}
=======

Search strategy and inclusion criteria {#Sec3}
--------------------------------------

We systematically searched the electronic medical databases (Medline, Embase and Google Scholar) up to November 6th, 2014 (date of last search) to identify relevant articles evaluating the macro-economic consequences of the six selected NCDs, specifically the impact on economic productivity of working age citizens. The complete search strategy is available in "Appendix [1](#Sec26){ref-type="sec"}". We defined the major NCDs of interest as CHD, stroke, chronic obstructive lung disease (COPD), type 2 diabetes mellitus (DM), cancer (lung, colon, breast and cervical) and chronic kidney disease (CKD). The step-wise inclusion and exclusion procedure is outlined in Fig. [1](#Fig1){ref-type="fig"}. Eligible study design included randomized controlled trials (RCTs), cohort, case--control, cross-sectional, systematic reviews, meta-analysis, ecological studies and modeling studies. We included studies that estimated the impact of at least one of the NCDs defined above on at least one of the following measures of macro-economic productivity: DALYs, economic costs related to reduced work productivity, absenteeism, presenteeism, (un) employment, (non-) return to work (RTW) after sickness absence and medical/sick leave. DALY is also considered as essentially it is an economic measure of human productive capacity for the affected individual and when taken together (e.g. all those in a company, society etc.) forms an economic measure also on the group level. Only studies involving adults (\>18 years old) were included, without any restriction on language or date.Fig. 1Flowchart of studies for the global impact of non-communicable diseases on macro-economic productivity

Study selection {#Sec4}
---------------

Two independent reviewers screened the titles and abstracts of the initially identified studies to determine if they satisfied the selection criteria. Any disagreements were resolved through discussion and consensus, or by consultation with a third reviewer. In order to ensure that all retrieved full texts (of the selected abstracts) satisfied the inclusion criteria appropriately, they were further assessed by two independent reviewers. We further screened the reference lists of all retrieved studies to retrieve relevant articles. Systematic reviews were not included in the data extraction but a supplementary scan of their reference lists was performed to identify any additional studies.

Data extraction {#Sec5}
---------------

A data collection form (DCF) was prepared to extract the relevant information from the included full texts, including study design, World Health Organization (WHO) region, participants, NCD-related exposure and macro-economic outcome characteristics. When evaluating economic costs, US dollars (USD) was used as outcome measure. If a study reported costs in another currency, the corresponding exchange rate to USD as reported by the study itself was used. However, if an exchange rate was not provided, we calculated USD applying the conversion rate for the indicated study time-period.

Quality evaluation {#Sec6}
------------------

To evaluate the quality of the included non-randomized studies, we applied the Newcastle--Ottawa Scale (NOS) \[[@CR3]\]. The NOS scale assesses the quality of articles in three domains: selection, comparability and exposure. 'Selection' assesses four items and a maximum of one star can be awarded for each item. 'Comparability' awards a maximum of two stars to the one item within the category. Finally, 'exposure' includes four items for which one star can be awarded. A quality score is made for each study by summing the number of stars awarded, and thus the NOS scale can have maximum of nine stars. We used this scale to assess the quality of case--control and cohort studies. For cross-sectional and descriptive studies, we used an adapted version of NOS scale ("Appendix [2](#Sec27){ref-type="sec"}").

Statistical methods {#Sec7}
-------------------

We aimed to pool the results using a random effects model. If pooled, results would be expressed as pooled relative risks with 95 % confidence intervals. Pooling possibility was conditional on the level of heterogeneity between studies.

Results {#Sec8}
=======

General characteristics of the included studies {#Sec9}
-----------------------------------------------

From 4542 references initially identified, a total of 126 unique studies met the inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). All eligible studies were published between 1984 and 2014. Of the 126 studies identified, 52 were from the WHO European Region, 53 from the Region of the Americas (of which all but two were from Canada or the United States of America \[USA\]), 16 from the Western Pacific Region, four were from the WHO African Region and one from the Eastern Mediterranean Region. We found no studies from South East Asia. The majority of the identified studies were observational in design, analyzed prospectively as well as cross-sectional. Two studies reported cross-sectional data from an RCT and six were modeling studies. National or hospital-based disease registries were often used to select patients, which were in some cases linked to national socio-economic databases to extract corresponding employment data. The control group, if used, was often a sample from the general population and sometimes sought within the same environment of the patients (e.g. same company). Many studies focused on the impact of more than one NCD on productivity. Most studies used one measure of productivity. Of all the published studies including cancers, cervical cancer was included in seven studies, breast cancer in 45, colon cancer in 24 and lung cancer in 16. Stroke was included in a total of 31 studies, COPD in 24, DM in 22 and CHD was included in 15 studies. Relevant data on CKD was included in only two of the studies and two of the studies mention NCDs in general.Table 1General characteristics of the included studiesSourcePeriod of surveillanceLocationWHO regionStudy designNumber in analysisGenderEthnicityReported NCDsAdepoju et al. \[[@CR71]\]2007--2012USARARetrospective376BothHispanic, non-Hispanic black, non-Hispanic whiteDMAhn et al. \[[@CR31]\]1993--2002South KoreaWPRCross-sectional1594FemaleNRBreast cancerAlavinia and Burdorf \[[@CR69]\]200410 EU countriesERCross-sectional11,462BothNRCVD, stroke, DMAlexopoulos and Burdorf \[[@CR54]\]1993--1995The NetherlandsERProspective cohort326MaleNRCOPDAnesetti-Rothermel and Sambamoorthi \[[@CR10]\]2007USARACross-sectional12,860BothWhite, Latino, African American, otherCOPD, CVD, stroke, DMAngeleri et al. \[[@CR80]\]NRItalyERProspective study180BothNRStrokeArrossi et al. \[[@CR23]\]2002--2004ArgentinaRACross-sectional120FemaleNRCervical cancerBains et al. \[[@CR44]\]2008--2009UKERProspective cohort50FemaleNRColon cancerBalak et al. \[[@CR34]\]2001--2007The NetherlandsERRetrospective cohort72FemaleNRBreast cancerBastida and Pagan \[[@CR81]\]1994--1999USARAPopulation based1021BothMexican AmericansDMBlack-Schaffer and Osberg \[[@CR82]\]1984--1986USARAProspective study79BothNRStrokeBogousslavsky and Regli \[[@CR83]\]NRSwitzerlandERProspective study41BothNRStrokeBoles et al. \[[@CR84]\]2001USARACross-sectional2264BothNRDMBouknight et al. \[[@CR37]\]2001--2002USARAProspective study416FemaleWhite, blackBreast CancerBradley and Bednarek \[[@CR85]\]1999USARACross-sectional184BothCaucasian, African-American, Hispanic, otherBreast cancer, colon cancer, lung cancerBradley et al. \[[@CR86]\]1992USARARetrospective study5974FemaleCaucasian, African-American, Hispanic, otherBreast cancerBradley et al. \[[@CR87]\]1992USARACross-sectional5728FemaleCaucasian, African-American, Hispanic, other.Breast cancerBradley et al. \[[@CR88]\]2001--2002USARAProspective study817FemaleNon-Hispanic White, Non-Hispanic African American, otherBreast cancerBradley et al. \[[@CR89]\]2001--2002USARAProspective study239FemaleNon-Hispanic White, Non-Hispanic African American, otherBreast cancerBradley and Dahman \[[@CR33]\]2007--2011USARACross-sectional828BothNon-Hispanic white, non-Hispanic black, otherBreast cancerBradley et al. \[[@CR40]\]2005USARAModelling studyNRBothNRColon cancerBradshaw et al. \[[@CR66]\]2000--2000South AfricaARModellingNRBothNRDMBroekx et al. \[[@CR90]\]1997--2004BelgiumERCost--of--Illness analysis20,439FemaleNRBreast cancerBurton et al. \[[@CR91]\]2002USARASurvey16,651BothNRDMCarlsen et al. \[[@CR45]\]2001--2009DenmarkEREpidemiological4343BothNRColon cancerCarlsen et al. \[[@CR29]\]2001--2011DenmarkERCross-sectional and propective14,750FemaleNRBreast cancerCatalá-López et al. \[[@CR13]\]2008SpainERCross-sectional37,563,454BothNRStrokeChoi et al. \[[@CR42]\]2001--2003South KoreaWPRProspective cohort305MaleNRColon cancerCollins et al. \[[@CR92]\]2002USARASurvey7797BothNRDMCostilla et al. \[[@CR22]\]2006New ZealandWPRModellingNRBothMaori and non-MaoriBreast cancer, colon cancer, lung cancer, cervical cancerDacosta DiBonaventura et al. \[[@CR53]\]2009USARACross-sectional20,024BothNon-Hispanic White, Non-Hispanic Black/African-American, Hispanic, otherCOPDDall et al. \[[@CR68]\]2007--2007USARAModellingNRNRNRDMDarkow et al. \[[@CR63]\]2001--2004USARACase--control4045BothNRCOPDDe Backer et al. \[[@CR93]\]1994--1998BelgiumERProspective cohort15,740BothNRDMEaker et al. \[[@CR94]\]1993--2003SwedenERCross-sectional28,566FemaleNRBreast CancerEarle et al. \[[@CR46]\]2003--2005USARAProspective cohort2422BothNon-Hispanic white, African American, Hispanics, Asian, mixed raceLung cancer, colon cancerEkwueme et al. \[[@CR26]\]1970--2008USARARetrospective cohort53,368FemaleWhite and BlackBreast cancerEtyang et al. \[[@CR6]\]2007--2012KenyaARProspective surveillance18,712BothNRCVD, Stroke, DMFantoni et al. \[[@CR38]\]2004--2005FranceERCross-sectional379FemaleNRBreast cancerFernandez de Larrea-Baz et al. \[[@CR95]\]2000SpainEREcological40,376,294BothNRBreast cancer, colon cancer, lung cancerFerro and Crespo \[[@CR96]\]1985--1992PortugalERProspective cohort215BothNRStrokeFu et al. \[[@CR97]\]2004--2006USARASurvey46,617BothWhite, black, Asian, otherDMGabriele and Renate \[[@CR18]\]2001--2004GermanyERProspective cohort70BothNRStrokeGenova-Maleras et al. \[[@CR4]\]2008SpainERModellingNRBothNRCVD, stroke, COPD, lung cancer, colon cancer, breast cancer, DMGordon et al. \[[@CR47]\]2003--2004AustraliaWPRProspective cohort975BothNRColon cancerHackett et al. \[[@CR19]\]2008--2010AustraliaWPRProspective cohort441BothNRStrokeHalpern et al. \[[@CR98]\]2000USARAEconomical evaluation447BothNRCOPDHansen et al. \[[@CR99]\]NRUSARACross-sectional203FemaleWhite and non-whiteBreast cancerHauglann et al. \[[@CR30]\]1992--1996NorwayERNational registry cohort3096FemaleNRBreast cancerHauglann et al. \[[@CR49]\]1992--1996NorwayERCase--control1480BothNRColon cancerHelanterä et al. \[[@CR65]\]2007FinlandERCross-sectional2637BothNRCKDHerquelot et al. \[[@CR100]\]1989--2007FranceERProspective cohort20,625BothNRDMHolden et al. \[[@CR52]\]2004--2006AustraliaWPRCross-sectional78,430BothNRCVD, COPD, DMHoyer et al. \[[@CR101]\]2007--2008SwedenERProspective cohort651FemaleNRBreast cancerJansson et al. \[[@CR59]\]1999SwedenEREconomic evaluation212BothNRCOPDKabadi et al. \[[@CR17]\]2005--2006TanzaniaARProspective surveillance study16BothNRStrokeKang et al. \[[@CR16]\]2008South KoreaWPREconomic EvaluationBothNRStrokeKappelle et al. \[[@CR102]\]1977--1992USARAProspective study296BothWhite, otherStrokeKatzenellenbogen et al. \[[@CR14]\]1997--2002Western AustraliaWPRModelling, ecologocial68,661BothIndigenous; non-indigenousStrokeKessler et al. \[[@CR70]\]1995--1996USARASurvey2074BothNRDMKlarenbach et al. \[[@CR64]\]1988--1994USARACross-sectional5558BothWhite, black, otherCVD, COPD, DM, CKDKotila et al. \[[@CR103]\]1978--1980FinlandERProspective255BothNRStrokeKremer et al. \[[@CR55]\]2000--2001AustraliaERCross-sectional826BothNRCOPDKruse et al. \[[@CR104]\]1980--2003DenmarkERCohort2212BothNRCHDLauzier et al. \[[@CR35]\]2003CanadaRAProspective cohort962FemaleNRBreast cancerLavigne et al. \[[@CR67]\]1999--1999USARACross-sectional472BothNRDMLeigh et al. \[[@CR105]\]1996USARAEcological study2,395,650BothNRCOPDLeng \[[@CR106]\]2004--2005SingaporeWPRRetrospective cohort29NRNRStrokeLenneman et al. \[[@CR107]\]2005--2009USARASurvey577,186BothWhite, black, Hispanic, Asian, otherDMLindgren et al. \[[@CR108]\]1994SwedenERCross-sectional393BothNRStrokeLokke et al. \[[@CR62]\]1998--2010DenmarkERCase--control262,622BothNRCOPDLokke et al. \[[@CR61]\]1998--2010DenmarkERCase--control1,269,162BothNRCOPDLopez--Bastida et al. \[[@CR15]\]2004Canary Islands, SpainERCross-sectional448BothNRStrokeMahmoudlou \[[@CR39]\]2008IranEMRCross-sectional72,992,154BothNRColon cancerMaunsell et al. \[[@CR32]\]1999--2000CanadaRACross-sectional57,307FemaleNRBreast cancerMayfield et al. \[[@CR109]\]1987USARASurvey35,000Both(non)African American, (non) HispanicDMMcBurney et al. \[[@CR110]\]1999--2000USARACross-sectional survey89BothCaucasian or minority/unknownCVDMolina et al. \[[@CR111]\]2004--2005SpainERCross-sectional347BothNRBreast cancer, colorectal cancer, lung cancerMolina Villaverde et al. \[[@CR112]\]NRSpainERCohort96FemaleNRBreast CancerMoran et al. \[[@CR5]\]2000--2029ChinaWPREcological and modelling1,270,000,000BothNRCVDNair et al. \[[@CR113]\]2000--2007USARAEconomic evaluation853,496BothNRCOPDNeau et al. \[[@CR114]\]1990--1994FranceERRetrospective67BothNRStrokeNiemi et al. \[[@CR115]\]1978--1980FinlandERRetrospective case-series46BothNRStrokeNishimura and Zaher \[[@CR58]\]1990--2002JapanWPRModelling study1,848,000BothNRCOPDNoeres et al. \[[@CR28]\]2002--2010GermanyERProspective cohort874FemaleNRBreast cancerNowak et al. \[[@CR60]\]2001GermanyERCross-sectional814BothNRCOPDO'Brien et al. \[[@CR116]\]NRUSARACross-sectional98BothCaucasian and African AmericanStrokeOhguri et al. \[[@CR117]\]2000--2005JapanWPRCross-sectional43BothNRLung cancer, colon cancerOrbon et al. \[[@CR56]\]1998--2000The NetherlandsERCross-sectional2010BothNRCOPDOsler et al. \[[@CR12]\]2001--2009DenmarkERCohort21,926BothNRCVDPark et al. \[[@CR48]\]2001--2006South KoreaWPRCross-sectional2538BothNRLung cancer, colon cancer, breast cancer, cervical cancerPark et al. \[[@CR118]\]2001--2006South KoreaWPRProspective study1602BothNRLung cancer, colon cancer, breast cancer, cervical cancerPeters et al. \[[@CR119]\]NRNigeriaARCross-sectional110BothNRStrokePeuckmann et al. \[[@CR120]\]1989--1999DenmarkERCross-sectional1316FemaleNRBreast cancerQuinn et al. \[[@CR20]\]1998--2008UKERProspective Cohort214BothNRStrokeRobinson et al. \[[@CR121]\]1985--1989UKERCross-sectional2104BothCaucasian, West-Indian, AsianDMRoelen et al. \[[@CR122]\]2001--2005The NetherlandsEREcological259FemaleNRBreast cancerRoelen et al. \[[@CR50]\]2004--2006The NetherlandsERRetrospective cohort300,024BothNRLung cancer, breast cancerSaeki and Toyonaga \[[@CR123]\]2006--2007JapanWPRProspective cohort325BothNRStrokeSasser et al. \[[@CR8]\]1998--2000USARAEconomic evaluation38,012FemaleNRBreast cancer, CVDSatariano et al. \[[@CR27]\]1984--1985 1987--1988USARACross-sectional1011FemaleWhite, blackBreast cancerShort et al. \[[@CR124]\]1997--1999USARACross-sectional1433BothWhite, non-white, undeterminedBreast cancerShort et al. \[[@CR11]\]2002USARACross-sectional6635BothNRCVD, stroke, COPD, DMSin et al. \[[@CR125]\]1988--1994USARACross-sectional12,436BothWhite, Black, otherCOPDSjovall et al. \[[@CR36]\]2004--2005SwedenEREcological study14,984BothNRBreast cancer, colon cancer, lung cancerSpelten et al. \[[@CR126]\]NRThe NetherlandsERProspective cohort235FemaleNRBreast cancerStewart et al. \[[@CR127]\]NRCanadaRACross-sectional378FemaleNRBreast cancerStrassels et al. \[[@CR128]\]1987--1988USARACross-sectional238BothAfrican American, White, otherCOPDSyse et al. \[[@CR51]\]1953--2001NorwayERCross-sectional population based1,116,300BothNRBreast cancer, lung cancer, colorectal cancerTaskila-Brandt et al. \[[@CR24]\]1987--1988 1992--1993FinlandERCross-sectional population based5098BothNRCervical cancer, breast cancer, colon cancer lung cancerTaskila et al. \[[@CR129]\]1997--2001FinlandERCross-sectional394FemaleNRBreast cancerTeasell et al. \[[@CR130]\]1986--1996CanadaRARetrospective cohort563BothNRStrokeTevaarwerk et al. \[[@CR43]\]2006--2008USA and PeruRACross-sectional530BothNon-Hispanic whites and whitesBreast cancer, lung cancer, colon cancerTimperi et al. \[[@CR131]\]2006--2011USARAProspective cohort2013FemaleWhites, Blacks, Hispanic, Asian, otherBreast CancerTorp et al. \[[@CR25]\]1999--2004NorwayERProspective Registry9646BothNRCervical cancer, breast cancer, colon cancer, lung cancerTraebert et al. \[[@CR21]\]2008BrazilRAModelling, ecologicalNRBothNRCervical cancer, breast cancer, colon cancer, lung cancervan Boven et al. \[[@CR57]\]2009The NetherlandsEREconomic evaluation45,137BothNRCOPDVan der Wouden et al. \[[@CR132]\]1978--1980The NetherlandsERCross-sectional313FemaleNRBreast cancerVestling et al. \[[@CR133]\]NRSwedenERRetrospective study120BothNRStrokeWang et al. \[[@CR134]\]NRUSARACross-sectional199BothNRCVD, COPD, diabetesWard et al. \[[@CR135]\]1993--1994USARACross-sectional2529BothMixed ethnicitiesCOPDWozniak et al. \[[@CR136]\]NRUSARARetrospective study203BothWhites, blacks and otherStrokeYaldo et al. \[[@CR41]\]2006--2009USARACase--control330BothNRColon CancerYabroff et al. \[[@CR137]\]2000USARACross-sectional496BothHispanic, non-Hispanic white, non-Hispanic black, otherBreast cancer, colon cancerZhao and Winget \[[@CR7]\]2003--2006USARARetrospective cohort10,487BothNRCVD (CHD)Zheng et al. \[[@CR9]\]2004AustraliaWPREconomic evaluationNRBothNRCVD (CHD)*AR* African Region, *COPD* chronic obstructive pulmonary disease, *CKD* chronic kidney disease, *CVD* cardiovascular disease, *DM* diabetes mellitus, *EMR* Eastern Mediterranean Region, *ER* European Region, *NCD* no-communicable diseases, *NR* not reported, *RA* Region of the Americas, *USA* United States of America, *WHO* World Health Organization, *WPR* Western Pacific Region

Measures of productivity {#Sec10}
------------------------

Measures of productivity impact in the available studies included DALYs, absenteeism, presenteeism, labor market (non-) participation, RTW, change in hours worked and medical/sickness leave. Most studies focused on the direct impact on the patient but a minority also examined the impact on caregivers/spouses. Outcomes were quantified using risks, proportions, odds, dollars, years and days. In some studies, time-to-event data was analyzed using Cox proportional-hazards regression. Adjusting for education, age and employment status was most frequently applied, although the measurement of education and employment was not consistently defined, measured or validated. A small minority of studies reported differences in impact according to ethnicity. Pooling of outcomes was not possible due to substantial heterogeneity across and within NCD groups (*I*^2^ \> 70 %).

Impact of cardiovascular disease on productivity {#Sec11}
------------------------------------------------

Of all DALYs on a population level in Spain (Table [2](#Tab2){ref-type="table"}a), 4.2 % were attributable to CHD \[[@CR4]\] with an estimated age-standardized rate of 4.7 per 1000 persons per year. In China, DALYs attributable to CHD were estimated to be 8,042,000 for the year 2000 and predicted to more than double in 2030, rising up to 16,356,000 \[[@CR5]\]. In the same study, the estimated DALY in 2000 was 16.1 per 1000 persons and predicted to be 20.4 in 2030 (estimate not accounted for age). A study from Kenya estimated the DALY to be 68 per 100,000 person-years of observation \[[@CR6]\]. CHD-related productivity loss in the USA was estimated to be 8539 USD per person per year (PP/PY), at 10175 USD PP/PY \[[@CR7]\] for absenteeism and 2698 USD PP/PY for indirect work-related loss \[[@CR8]\]. Total absenteeism-related costs in Australia were estimated at 5.69 billion USD, mortality-related costs at 23 million USD and costs related to lower employment at 7.5 billion USD \[[@CR9]\]. An estimated 4.7 working days PP/PY were lost in the USA owing to CHD \[[@CR10]\]. Also in the USA, the odds of experiencing limited amount of paid work due to illness were significantly higher for those with CHD compared to the control group, with an odds ratio (OR) of 2.91 for women (95 % CI 2.34--3.61) and 2.34 for men (95 % CI 1.84--2.98) \[[@CR11]\]. In Denmark workforce participation increased with increasing time from 37 % after 30 days to 65 % after 5 years of diagnosis \[[@CR12]\]. In a study conducted in 10 European Union (EU) countries, no difference was found for the risk of non-participation in the labor force between those with and without self-reported CHD with an OR of 0.96 (95 % CI 0.66--1.40).Table 2Results of the included studies investigating the impact of CVD on productivityStudyType of outcomeOutcome specified asAssessment typePoint estimateSD for mean95 % CIQuality score*a*Alavinia and Burdorf \[[@CR69]\]UnemploymentNon-participation in the labor forceORNR0.66--1.404Anesetti-Rothermel and Sambamoorthi \[[@CR10]\]Sick leaveWork days in last year lost due to illnessMean4.7007.89 (SE)NR6Etyang et al. \[[@CR6]\]DALYsRate per 100,000 person year of observationRate68NRNR5Genova-Maleras et al. \[[@CR4]\]DALYsRate per 1000 age standardisedRate4.7NRNRNAPercentage of all causes of mortalityPercent4.2NRNRHolden et al. \[[@CR52]\]Productivity LossAbsenteeism (no. days or part days missed from work in last 4 weeks)IRR1.17NR1.03--1.323Presenteeism (self-rated score of overall performance over last 4 weeks)IRR1.65NR1.22--2.21Klarenbach et al. \[[@CR64]\]UnemploymentNon-participation in labor forceOR1.27NR0.45--3.536Kruse et al. \[[@CR104]\]Labor market participationLabor market withdrawal a year after the disease debut (controls 7 %)Percent21NRNR6Risk of labor market withdrawalHR1.32NR1.11--1.57McBurney et al. \[[@CR110]\]Return to workReturn to work at a mean of 7.5 monthsPercent76.4NRNR4PresenteeismPerceived work performanceMean3.60.52NRMoran et al. \[[@CR5]\]DALYsObserved period 2000Count80,420,00NRNRNAObserved period 2000Rate16.1NRNRPredicted 2010Count107,300,00NRNRPredicted 2010Rate16.5NRNRPredicted 2020Count134,220,00NRNRPredicted 2020Rate18.2NRNRPredicted 2030Count16356000NRNRPredicted 2030Rate20.4NRNROsler et al. \[[@CR12]\]Labor market participationWorkforce participation 30 days after diagnosis (among patients who were part of the workforce at time of diagnosis)Percent37.2NRNR5Workforce participation 1 year after diagnosis (among patients who were part of the workforce at time of diagnosis)Percent40.1NRNRWorkforce participation 2 years after diagnosis (among patients who were part of the workforce at time of diagnosis)Percent45.0NRNRWorkforce participation 5 years after diagnosis (among patients who were part of the workforce at time of diagnosis)Percent65.2NRNRSasser et al. \[[@CR8]\]Productivity loss costsAttributable annual indirect work-loss costs per patientUSD2698NRNR8Short et al. \[[@CR124]\]UnemploymentLimited amount of paid work possible due to illness femaleOR2.91NR2.34--3.615Limited amount of paid work possible due to illness maleOR2.341.84--2.98Wang et al. \[[@CR134]\]AbsenteeismAnnual excess in daysMean8.87.0 (SE)NR4PresenteeismAnnual excess in daysMean8.911.8 (SE)NRAbsenteeism and presenteeism combinedAnnual excess in daysMean16.312.7 (SE)NRZhao and Winget \[[@CR7]\]Productivity loss costsShort term 1 year productivity costs/per personUSD8539NRNR6Absenteeism 1 year productivity costs/per personUSD10175NRNRZheng et al. \[[@CR9]\]Productivity loss costsAbsenteeism related totalUSD568,500,000NRNRNAMortality relatedUSD235,650,00NRNRDue to lower employmentUSD750,000,000NRNR*b*Alavinia and Burdorf \[[@CR69]\]UnemploymentNon participation in the labour forceOR1.110NR0.530--2.3204Anesetti-Rothermel and Sambamoorthi \[[@CR10]\]Sick leaveWork days in last year lost due to illnessMean17.9605.83 (SE)--6Angeleri et al. \[[@CR80]\]Return to workReturn to work 12--196 months (mean 37.5) in hemiplegic patientsPercent20.64NRNR6Black-Schaffer and Osberg \[[@CR82]\]Return to workReturn to work at 6--25 months post-rehabilitationPercent49NRNR3Time return to work in months from rehabilitationMean3.12.12NRReturn to prior job at 6--25 months post-rehabilitationPercent43NRNRBogousslavsky and Regli \[[@CR83]\]Return to workReturn to work 6--96 months (mean 46)Count19NRNR3Catalá-López et al. \[[@CR13]\]DALYsTotalCount418,052NRNR4MaleCount220,005NRNRFemaleCount198,046NRNREtyang et al. \[[@CR6]\]DALYsRate per 100,000 person year of observationRate166NRNR5Ferro and Crespo \[[@CR96]\]UnemploymentInactive at end of follow-up (mean 33.4 months, range 1--228 months)Percent27NRNR4Gabriele and Renate \[[@CR18]\]Return to WorkReturn to work after 1 year of those employedPercent26.7NRNR4Genova-Maleras et al. \[[@CR4]\]DALYsRate per 1000 age standardisedRate3.8NRNRNAPercentage of all causes of mortalityPercent3.5NRNRHackett et al. \[[@CR19]\]Return to workReturn to work 1 year after eventPercent75NRNR2Kabadi et al. \[[@CR17]\]Return to workAverage months off work in 6 month follow up periodMean6NRNR4CostsMean productivity losses due to strokeUSD213NRNRKang et al. \[[@CR16]\]Productivity loss costsMale, total modelled costs per severe stroke per yearUSD537,724NRNRNAFemale, total modelled costs per severe stroke per yearUSD171,157NRNRKappelle et al. \[[@CR102]\]UnemploymentUnemployment at 0.02--16 years after event (mean 6 years)Percent58NRNR5Katzenellenbogen et al. \[[@CR14]\]DALYsMaleCount26,315NRNRNAFemaleCount30,918NRNRMale, rate per 10,000 people, age standardized---indigenousRate2027NR1909--2145Female, rate per 10,000 people, age standardized---indigenousRate1598NR1499--1697Male, rate per 10,000 people, age standardized---non-indigenousRate640NR633--648Female, Rate per 10,000 people, age standardized---non-indigenousRate573NR567--580Klarenbach et al. \[[@CR64]\]UnemploymentNon-participation in labour forceOR2.21NR(0.7--7)6Kotila et al. \[[@CR103]\]Return to workReturn to work after 12 monthsPercent59NRNR4Leng \[[@CR106]\]Return to workReturn to work in 1 yearPercent55.0NRNRNALindgren et al. \[[@CR108]\]Productivity loss costsIndirect costs during one earUSD17,844NR12,275--23,8644Lopez-Bastida et al. \[[@CR15]\]Productivity loss costsIndirect per person, 1 year after strokeUSD26966462NR5Indirect per person, 2 year after strokeUSD13934754NRIndirect per person, 3 year after strokeUSD13624931NRCaregivers cost per person per year, 1 year after strokeUSD14,73214,616NRCaregivers cost per person per year, 2 year after strokeUSD15,62114,693NRCaregivers cost per person per year, 3 year after strokeUSD13,75915,470NRNeau et al. \[[@CR114]\]Return to workReturn to work in same position as prior to strokePercent54NRNR3Return to work after 0--40 month (mean 7.8)Percent73NRNR6Niemi et al. \[[@CR115]\]Return to workReturn to work after 4 yearsPercent54NRNRO'Brien et al. \[[@CR116]\]Return to workReturn after 6--18 monthsPercent56.0NRNR1Peters et al. \[[@CR119]\]Return to workReturn to work after 3--104 months (mean 19.5)Percent55NRNR3Quinn et al. \[[@CR20]\]Return to Workunemployment at 1 year follow upPercent47NRNR3Roelen et al. \[[@CR122]\]Return to WorkReturn to work after 3--104 months (mean 19.5)Percent55.0NRNR6Saeki and Toyonaga \[[@CR123]\]Return to WorkReturn to work at 18 monthsPercent55.0NRNR6Short et al. \[[@CR124]\]UnemploymentLimited amount of paid work possible due to illness femaleOR2.26NR1.56--2.265Limited amount of paid work possible due to illness maleOR3.86NR2.55--3.60Teasell et al. \[[@CR130]\]Return to workReturn to work at 3 monthsPercent20NRNR3Return to work full-time at 3 monthsPercent6NRNRVestling et al. \[[@CR133]\]Return to workReturn to work mean of 2.7 yearsPercent41NRNR3Time to return to work in monthsMean11.99NRReturn to work with reduced work hoursPercent21NRNRWozniak et al. \[[@CR136]\]Return to workReturn to work after 1 yearPercent53NRNR6Return to work after 2 yearPercent44NRNR*c*Arrossi et al. \[[@CR23]\]Return to workReduced in hours worked (patients)Percent45NRNR4Change of work (pat.)Percent5NRNRStarting paid work (pat.)Percent14NRNRIncreased in hours worked (pat.)Percent11NRNROdds of work interruption (pat.)OR4NRNROdds of reduction in hours worked (pat.)OR1NRNROdds of starting paid work (pat.)OR2NRNROdds of increase in hours worked (pat.)OR1NRNRWork interruption (caregivers)Percent3NRNRReduction in hours worked (caregivers)Percent61NRNRChange of work (caregivers)Percent2NRNRStarting paid work (caregivers)Percent5NRNRIncreased in hours worked (caregivers)Percent24NRNRWork interruption (patients)Percent28NRNRCostilla et al. \[[@CR22]\]DALYsFemaleCount1016NRNRNAPercentage of all cancers, femalePercent1.6NRNRRate per 10,000 people (age standardized)Rate84NRNRPark et al. \[[@CR48]\]Labour market participationTime until job loss between patients and controls Cox PHHR1.32NR0.95--1.827Park et al. \[[@CR118]\]Labour market participationTime until job loss between patients and controls Cox PHHR1.68NR1.40--2.015Time until re-employment between patients and controls Cox PHHR0.67NR0.46--0.97Taskila-Brandt et al. \[[@CR24]\]Labor market participationEmployment status cancer survivors 2--3 years post-diagnosis compared to general population (58 vs. 75 %)RR0.77NR0.67--0.906Traebert et al. \[[@CR21]\]Labor market participationEmployment in 5 years from diagnosisOR0.92NR0.63--1.349Traebert et al. \[[@CR21]\]DALYRate per 10,000 people (age standardized)Rate118.7NRNRNAPercentage of all cancers (in females)Percent13.4NRNRTotalCount2516.1NRNR*d*Ahn et al. \[[@CR31]\]Labour market drop-outNot working current for cancer survivors versus the general population (adjusted)OR1.6801.3502.1003OR of not working for cancer survivors of currently not working compared with their employment status at the time of diagnosisOR1.6301.5101.760UnemploymentAdjusted OR for not working at the time of diagnosis versus the general populationOR1.2100.9601.530Balak et al. \[[@CR34]\]Sick leaveMonths to fully return to workMean11.4NRNR3Months to return to partial workMean9.5NRNRBouknight et al. \[[@CR37]\]Return to workReturn to work in 12 months after diagnosisPercent82NRNR5Return to work in 18 months after diagnosisPercent83NRNRBradley and Bednarek \[[@CR85]\]UnemploymentUnemployed 5--7 years after diagnosis for cancer survivorsPercent54.8NRNR5Unemployed 5--7 years after diagnosis for cancer survivorsPercent45.4NRNRBradley et al. \[[@CR86]\]Labor market participationProbability of working of breast cancer patients compared to controls at mean of 7 yearsPercent−74NR8Bradley et al. \[[@CR87]\]Labor market participationProbability of working of breast cancer patients compared to controls at mean of 7.15 yearsPercent−104NR5Bradley et al. \[[@CR89]\]EmploymentProbability of being employed for patients compared to controls at 6 monthsPercent−25NRNR7Reduced weekly hours of work for patients compared to controls after 6 monthsPercent−18NRNRBradley et al. \[[@CR40]\]AbsenteeismDays absent from work evaluated at 6 months after diagnosisMean44.555.2NR7Bradley and Dahman \[[@CR33]\]Labor market participationProbability of stopping work at 2 months post diagnosis (husbands of female patients)OR2.642NR0.848--8.2255Labor market participationProbability of stopping work at 9 months post diagnosis (husbands of female patients)OR0.843NR0.342--2.198ProductivityOdds of decrease in weekly hours at 2 months post diagnosis (husbands of female patients)OR1.4490.957--2.192ProductivityOdds of decrease in weekly hours at 9 months post diagnosis (husbands of female patients)OR1.0570.69--1.62ProductivityChange in weekly hours at 2 months post diagnosis (husbands of female patients) (hours)Count−0.007(0.885) SENRProductivityChange in weekly hours at 9 months post diagnosis (husbands of female patients) (hours)Count1.814(1.261) SENRBroekx et al. \[[@CR90]\]ProductivityIndirect costs work per patient per year (attributable)USD5248NRNR3Indirect costs housekeeping per patient per year (attributable)USD2034NRNRIndirect costs mortality per patient per year (attributable)USD14,203NRNRSick leave days per yearUSD47.2NRNRTotal indirect costs per patient per year (attributable)USD21,485NRNRCarlsen et al. \[[@CR45]\]Unemployment% of working women 2 years after treatmentPercent72NRNR5Costilla et al. \[[@CR22]\]DALYsDALYs % of all cancersPercent27.2NRNRNARate per 10,000 people (age standardized)Rate1065NRNRDALYsCount17,840NRNREaker et al. \[[@CR94]\]Sick leavePercentage difference of sickness absence comparing patients 5 years after diagnosis with women without breast cancerPercent10.100NRNR7Percentage difference of sickness absence comparing patients 3 years after diagnosis with women without breast cancerPercent11.100NRNREkwueme et al. \[[@CR26]\]Productivity lossMortality-related total lifetime productivity loss (whites)USD3,920,400,000NRNR4Mortality-related total lifetime productivity loss (blacks)USD1323200000NRNRMortality-related total lifetime productivity loss/per death (all)USD1,100,000NRNRMortality-related total lifetime productivity loss/per death (whites)USD1,090,000NRNRMortality-related total lifetime productivity loss/per death (blacks)USD1,110,000NRNRMortality-related total lifetime productivity loss (all)USD5,488,600,000NRNRFantoni et al. \[[@CR38]\]Return to workReturn to work 12 months after starting treatmentPercent54.3NRNR5Return to work after 3 years after starting treatmentPercent82.1NRNRSick leaveDuration of sick leave 36 months after starting treatment in monthsMean1.8NR9.2--12.1Fernandez de Larrea-Baz N et al. \[[@CR95]\]DALYsRate per 10,000 people, age standardized, maleRate2NRNR4Rate per 10,000 people, age standardized, totalCount77,382NRNRRate per 10,000 people, age standardized, femaleRate374NRNRGenova-Maleras et al. \[[@CR4]\]DALYsRate per 1,000 people, age standardizedRate1.6NRNRNAPercentage of all causes of mortalityPercent1.4NRNRHansen et al. \[[@CR99]\]PresenteeismAverage score difference on work limitation scale between cases and non-cancer controlsMean2.9NRNR5Hauglann et al. \[[@CR30]\]UnemploymentUnemployment at 9 years in femalesPercent18NRNR9Hoyer et al. \[[@CR101]\]UnemploymentUnemployment at follow upPercent26NRNR4Lauzier et al. \[[@CR35]\]Sick leavePercent taking sick leave for 1 week or morePercent90.7NRNR6Weeks of absence due to breast cancerCount32.3NRNRMaunsell et al. \[[@CR32]\]UnemploymentUnemployment among disease free survivorsRisk ratio1.35NR1.08--1.77UnemploymentUnemployment among survivors with new breast cancer eventRisk ratio2.24NR1.57--3.18UnemploymentUnemployment among all survivors (3 years after diagnosis)Risk ratios1.46NR1.18--1.81Productivity lossSurvivors reporting part-time working compared to controls (3 years after diagnosis)Percent4NRNRProductivity lossChange in working hours among survivors--change over time compared to controls (3 years after diagnosis)Mean−2.6NRNRMolina et al. \[[@CR111]\]Return to workReturn to work at mean time since diagnosis(32.5 months)Percent56NRNR5Molina Villaverde et al. \[[@CR112]\]Return to workReturn to work by end of treatmentPercent56NRNRNANoeres et al. \[[@CR28]\]Unemployment6 years after diagnosisPercent43.2NRNR51 year after diagnosisPercent49.8NRNRPark et al. \[[@CR48]\]Labour market participationTime until job loss (months)Mean36NR7Time until 25 % of patients were re-employment (months)Mean30NRPark et al. \[[@CR118]\]Labour market participationCox proportional analysis comparing time until job loss between patients and controlsHR1.83NR1.60--2.105Cox proportional analysis comparing time until re-employment between patients and controlsHR0.61NR0.46--0.82Peuckmann et al. \[[@CR120]\]Labor market participationAge-standardized prevalence of employment at 5--15 years post primary surgeryPercent49NRNR4Age standardized risk ratio (SRR) of employment at 5--15 years post primary surgerySRR1.02NR0.95--1.10Age-standardized prevalence of sick leave at 5--15 years post primary surgeryPercent12NRNRAge standardized risk ratio (SRR) of sick leave at 5--15 years post primary surgerySRR1.28NR0.88--1.85Roelen et al. \[[@CR50]\]Return to workTime to return to full-time work (days)Count349.0NR329--3696Time to return to part-time work (days)Count271.0NR246--296Roelen et al. \[[@CR112]\]Return to workReturn to work at 2 yearsPercent89.4NRNR4Sick leaveDays of absence due to breast cancerCount349NRNRSasser et al. \[[@CR8]\]Productivity loss costsAttributable annual indirect work-loss costs per female patientUSD5944.0NRNR8Satariano et al. \[[@CR27]\]Return to work3 months after diagnosis (white women)Percent74.2NRNR3Return to work3 months after diagnosis (black women)Percent59.6NRNRSick leave3 months after diagnosis (white women)Percent25.8NRNRSick leave3 months after diagnosis (black women)Percent40.4NRNRShort et al. \[[@CR124]\]UnemploymentThe chances of quitting work/unemployment 1--5 years after diagnosisOR0.44NR0.20--0.955Sjovall et al. \[[@CR36]\]Sick leaveDays sick leave taken before return to workCount90NRNR5Spelten et al. \[[@CR126]\]Return to workTime to return to work after diagnosis analyzed using Cox PHHR0.45NR0.24--0.864Stewart et al. \[[@CR127]\]UnemploymentUnemployment assessed at least at 2 years after diagnosis, mean of 9 yearsPercent41NRNR3Syse et al. \[[@CR51]\]Labor market participationEmployment probability in the year 2001 of cancer survivors compared to general populationOR0.74NR0.65--0.846Taskila-Brandt et al. \[[@CR24]\]Labor market participationEmployment status of cancer survivors 2--3 years post-diagnosis compared to general population (61 vs. 65 %)RR0.95NR0.92--0.986Taskila et al. \[[@CR129]\]Work abilityCurrent work ability assessed between 0 and 10 by questionnaire (reference group 8.37)Mean8.23NRNR8Tevaarwerk et al. \[[@CR43]\]UnemploymentUnemploymentPercent19.4NRNR6Timperi et al. \[[@CR131]\]Unemployment6 months post diagnosisPercent52.0NRNR4Torp et al. \[[@CR25]\]Labor market participationEmployment 5 years from diagnosisOR0.74NR0.63--0.879Traebert et al. \[[@CR21]\]DALYsPercentage of all cancers, femalePercent21.9NRNRNARate per 10,000 people, age standardized, maleRate3.2NRNRPercentage of all cancers, malePercent0.3NRNRTotalCount6032.3NRNRRate per 10,000 people, age standardized, femaleRate195NRNRVan der Wouden et al. \[[@CR132]\]Labor market participationChanges in employment status at least 5 years cancer freePercent−7NRNR3Maintained employment status after diagnosisPercent16NRNRYabroff et al. \[[@CR137]\]Labor market participationJob in past 12 months, compared to control group (45.9 % with a *p* value \<0.001 for difference)Percent36.9NR31.0--42.86Sick leaveDays lost from wok due to health problems in past 12 months compared to control group (5.7 % with a *p* value \<0.001 for difference)Mean21.0NR28.4--58.3PresenteeismLimited in work due to health issues compared to control group (17.6 % with a *p* value of \<0.001 for difference)Percent22.5NR17.4--27.6*e*Bains et al. \[[@CR44]\]Unemployment6 months after surgeryPercent61NRNR2Bradley et al. \[[@CR40]\]Productivity lossAnnual productivity losses total 2020 modelled (millions)USD21,780NRNRNAAnnual productivity losses total 2005 (millions)USD20,920NRNRBradley and Bednarek \[[@CR85]\]UnemploymentUnemployed 5--7 years after diagnosis cancer survivorsPercent54.8NRNR5Unemployed 5--7 years after diagnosis spouse of cancer survivorsPercent53NRNRCarlsen et al. \[[@CR29]\]Return to WorkReturn to work after 1 year after diagnosisPercent69NRNR8Choi et al. \[[@CR42]\]UnemploymentLost job at 24 months in malesPercent46NRNR7Costilla et al. \[[@CR22]\]DALYsFemaleCount8431NRNRNA% of all cancers (Female)Percent12.9NRNRRate per 10,000 people (age standardised, Female)Rate333NRNRMaleCount8316NRNR% of all cancers (Male)Percent13.5NRNRRate per 10,000 people (age standardised, Male)Rate414NRNREarle et al. \[[@CR46]\]UnemploymentUnemployment at 15 monthsPercent65NRNR4Fernandez de Larrea-Baz N et al. \[[@CR95]\]DALYsRate per 10,000 people, age standardized, femaleRate212NRNR4Rate per 10,000 people, age standardized, maleRate284NRNRRate per 10,000 people, age standardized, totalCount99,833NRNRGenova-Maleras et al. \[[@CR4]\]DALYsRate per 1000 people, age standardizedRate2.3NRNRNAPercentage of all causes of mortalityPercent2.1NRNRGordon et al. \[[@CR47]\]Return to workWorking 1 year after diagnosis (%)Percent65NRNR5Hauglann et al. \[[@CR49]\]Return to work% of employed that were on sick-leave at some point after 1 year of diagnosisPercent859Sickness absence for CRC localized, the OR is for 3 years after diagnosisOdds Ratio2.611.364.95Sickness absence for CRC regional, the OR is for 3 years after diagnosisOdds Ratio1.090.562.11Sickness absence for CRC distant, the OR is for 3 years after diagnosisOdds Ratio2.300.570.927Mahmoudlou \[[@CR39]\]DALYsTotal burden of colorectal cancer according to DALY in Iran in 2008Count52,534NRNR8DALYs for men in 2008Count29,928NRNRDALYs for women in 2008Count22,606NRNRMolina et al. \[[@CR111]\]Return to workReturn to work at mean time since diagnosis(32.5 months)Percent55NRNR5Ohguri et al. \[[@CR117]\]Sick leaveAttendance rate after return to work of employees with disease compared to controls (*p* value 0.67)Percent86NRNR4Park et al. \[[@CR48]\]Return to workTime until re-employment (patients after job loss) Cox PH analysisHR0.96NR0.7--1.327UnemploymentCox PH analysis time until job lossHR1.04NR0.91--1.2Park et al. \[[@CR118]\]Labour market participationCox PH analysis comparing time until job loss between patients and controlsHR1.69NR1.50--1.905Cox PH analysis comparing time until re-employment between patients and controlsHR0.57NR0.43--0.75Sjovall et al. \[[@CR36]\]Sick leaveDays sick leaveCount115NRNR5Syse et al. \[[@CR51]\]EmploymentEmployment probability in year 2001 of cancer survivors compared to general population--menOR0.67NR0.58--0.786Employment probability in year 2001 of cancer survivors compared to general population--womenOR0.74NR0.65--0.84Taskila-Brandt et al. \[[@CR24]\]Labor market participationEmployment status of cancer survivors 2--3 years post-diagnosis compared to general population (53 vs. 59 %)RR0.90NR0.81--0.996Tevaarwerk et al. \[[@CR43]\]UnemploymentUnemploymentPercent24.1NRNR6Torp et al. \[[@CR25]\]Labour market participationEmployment in 5 years from diagnosis (females)OR0.84NR0.53--1.359Employment in 5 years from diagnosis (male)OR0.7NR0.43--1.15Traebert et al. \[[@CR21]\]DALYsRate per 10,000 people, age standardized, femaleRate82.6NRNRNAPercentage of all cancers, femalePercent9.3NRNRRate per 10,000 people, age standardized, maleRate73.1NRNRPercentage of all cancers, malePercent7.5NRNRTotalCount4867.2NRNRYabroff et al. \[[@CR137]\]Labor market participationJob in past 12 months, compared to control group (45.9 % with a *p* value \<0.001 for difference)Percent22.4NR15.6--29.36Sick leaveDays lost from wok due to health problems in past 12 months compared to control group (5.7 % with a *p* value \<0.001 for difference)Mean10.0NR3.4--16.7PresenteeismLimited in work due to health issues compared to control group (17.6 % with a *p* value of \<0.001 for difference)Percent32.4NR24.2--40.6Yaldo et al. \[[@CR41]\]AbsenteeismMean higher absenteeism costs after 1 year of diagnosis compared to controlsUSD4245NRNR7*f*Bradley and Bednarek \[[@CR85]\]UnemploymentUnemployed 5--7 years after diagnosis cancer survivorPercent62.2NRNR5Unemployed 5--7 years after diagnosis spouse of cancer survivor51.3NRNRCostilla et al. \[[@CR22]\]DALYsFemaleCount9334NRNRNA% of all cancers (female)Percent14.3NRNRRate per 10,000 people (age standardised, female)Rate849NRNRMaleCount9806NRNR% of all cancers (male)Percent15.9NRNRRate per 10,000 people (age standardised, male)Rate775NRNREarle et al. \[[@CR46]\]UnemploymentUnemployment at 15 monthsPercent79NRNR4Fernandez de Larrea-Baz N et al. \[[@CR95]\]DALYsRate per 10,000 people (age standardised, female)Rate98NRNR4Rate per 10,000 people (age standardised, male)Rate736NRNRRate per 10,000 people (age standardised, all)Count165,611NRNRGenova-Maleras et al. \[[@CR4]\]DALYsPercentage of all causes of mortalityPercent3.4NRNRNARate per 1000 people, age standardizedRate3.8NRNRMolina et al. \[[@CR111]\]Return to workReturn to work at mean time since diagnosis(32.5 months)Percent15NRNR5Ohguri et al. \[[@CR117]\]Sick leaveAttendance rate after return to work of employees with disease compared to controls (*p* value 0.59)Percent75NRNR4Park et al. \[[@CR48]\]Labour market participationTime until job lossCox PH1.31NR1.12--1.537Time until re-employment (patients after job loss)Cox PH0.79NR0.55--1.16Park et al. \[[@CR118]\]Labour market participationCox proportional analysis comparing time until job loss between patients and controlsHR2.22NR1.93--2.655Cox proportional analysis comparing time until re-employment between patients and controlsHR0.45NR0.32--0.64Roelen et al. \[[@CR122]\]Return to workTime to return to full-time work (days)Count484.0NR307--4476Time to return to part-time work (days)Count377.0NR351--617Syse et al. \[[@CR51]\]EmploymentEmployment probability in year 2001 of cancer survivors compared to general population--menOR0.37NR0.31--0.456Employment probability in year 2001 of cancer survivors compared to general population--womenOR0.58NR0.48--0.71Sjovall et al. \[[@CR36]\]Sick leaveDaysCount275NRNR5Taskila-Brandt et al. \[[@CR24]\]Labor market participationEmployment status of cancer survivors 2--3 years post-diagnosis compared to general population (19 vs. 43 %)RR0.45NR0.34--0.596Tevaarwerk et al. \[[@CR43]\]UnemploymentUnemploymentPercent33NR6Torp et al. \[[@CR25]\]UnemploymentEmployment in 5 years from diagnosis (male)OR0.39NR0.18--0.839Employment in 5 years from diagnosis (female)OR0.39NR0.19--0.81Traebert et al. \[[@CR21]\]DALYsRate per 10,000 people, age standardized, femaleRate87.6NRNRNAPercentage of all cancers, femalePercent9.8NRNRRate per 10,000 people, age standardized, maleRate239.9NRNRPercentage of all cancers, malePercent24.5NRNRTotalCount10,832.2NRNR*g*Alexopoulos and Burdorf \[[@CR54]\]Sick leaveDays of sick leave during 2 year follow up attributable to COPDMean8.53NRNR2Anesetti-Rothermel and Sambamoorthi \[[@CR10]\]Sick LeaveWork days in last year lost due to illnessMean8.6000.76 (SE)NR6Dacosta DiBonaventura et al. \[[@CR53]\]Productivity lossPercentage reporting absenteeism (difference between cases of COPD and controls)Percent4.190NRNR7Absenteeism hours (over last 7 days) (difference between COPD cases and controls)Mean1.250NRNRPercentage reporting presenteeism (difference between cases of COPD and controls)Percent16.550NRNREstimated number of hours of presenteeism in last 7 days (difference between COPD cases and controls)Mean4.780NRNRPercentage of those reporting work impairment (difference between cases of COPDand controls)Percent17.280NRNRPercentage reporting absenteeism (difference between cases of COPD and controls)Percent2.330NRNRAbsenteeism hours (over last 7 days) (difference between cases of COPD and controls)Mean0.330NRNRPercentage reporting presenteeism (difference between cases of COPD and controls)Percent10.230NRNREstimated number of hours of presenteeism in last 7 days (difference between cases of COPD and controls)Mean2.070NRNRPercentage of those reporting work impairment (difference between cases of COPD and controls)Percent11.530NRNRDarkow et al. \[[@CR63]\]Productivity lossIndirect per person per yearUSD9815NR8384--112466Genova-Maleras et al. \[[@CR4]\]DALYsRate per 1000 age standardisedRate2.6NRNR2Percentage of all causes of mortalityPercent2.3NRNRHalpern et al. \[[@CR98]\]Productivity lossCosts due to work loss up from 45 years up to age of retirement per patient per dayUSD100.55NRNR6Days lost per patient of working age per yearMean18.7NRNRDays lost per caregiver of working age per yearMean1.7NRNRUnemploymentUnemployment due to conditionPercent34NRNRHolden et al. \[[@CR52]\]Productivity lossAbsenteeism (no. of full/part days missed from work in last 4 weeks)IRR1.57NR1.33--1.863Presenteeism (self-rated score of overall performance in last 4 weeks)IRR1.22NR1.04--1.43Jansson et al. \[[@CR59]\]Productivity lossIndirect per person per yearUSD749NRNR6Kremer et al. \[[@CR55]\]UnemploymentPercentage of who stopped work (among people in work) because of the onset of COPDPercent39NRNR5Leigh et al. \[[@CR105]\]Productivity lossTotal indirect costs in 1996 in billions of dollarsUSD21,400NRNR3Lokke et al. \[[@CR62]\]Unemployment% receiving income from employmentPercent16.7NRNR7Productivity lossIndirect costs per patient before the diagnosisUSD4266NRNRindirect costs per patient after diagnosisUSD2816NRNRLokke et al. \[[@CR61]\]Productivity lossIndirect costs per patient before the diagnosisUSD5912NRNR9indirect costs per patient after diagnosisUSD3819NRNRUnemployment% of spouses receiving income from employmentPercent36.9NRNRNair et al. \[[@CR113]\]Productivity lossShort term 1 year productivity costs/per personUSD527NRNR9Absenteeism 1 year productivity costs/per personUSD55NRNRTotal costsUSDNRNRNishimura and Zaher \[[@CR58]\]Productivity lossModelled total annual costs per year in country (millions)USD1471NRNR2Modelled indirect per patientUSD262NRNRDays modelled per personCount8.1NRNRNowak et al. \[[@CR60]\]Productivity lossearly retirement (per patient/year) (all COPD stages)USD566NRNR3early retirement (per patient/year) (light COPD)USD489NRNRearly retirement (per patient/year) (medium COPD)USD567NRNRearly retirement (per patient/year) (severe COPD)USD1064NRNRdisability (per patient/year) (all COPD stages)USD398NRNRdisability (per patient/year) (light COPD)USD459NRNRdisability (per patient/year) (medium COPD)USD249NRNRdisability (per patient/year) (severe COPD)USD340NRNROrbon et al. \[[@CR56]\]UnemploymentUnemploymentPercent53.8NRNR4Sin et al. \[[@CR125]\]EmploymentAdjusted probability of being in work force for those with self-reported COPD compared to those without self-reported COPDPercent−3.9NR−1.3 to −6.44Productivity lossTotal loss productivity cost in 1994 in billionsUSD9.9NRNRShort et al. \[[@CR124]\]UnemploymentLimited amount of paid work possible due to illness (female)OR2.63NR2.03--3.425Limited amount of paid work possible due to illness (male)OR4.89NR3.46--6.9Strassels et al. \[[@CR128]\]Productivity lossNumber of lost work days COPD relatedMean1.0NR\<0.1--2.05Number of restricted activity days COPD relatedMean15.9NR10.3--21.5van Boven et al. \[[@CR57]\]Productivity lossCosts total per patient a year (2009)USD938NRNR6Costs in total (2009)USD88,340,000NRNRAbsenteeismDays total per patient (2009)Count10.7NRNRDays total (2009)Count482,966NRNRWang et al. \[[@CR134]\]AbsenteeismAnnual excess in daysMean19.48.9 (SE)NR4PresenteeismAnnual excess in DaysMean27.515.6 (SE)NRAbsenteeism & Presenteeism combinedAnnual excess in daysMean42.917.0 (SE)NRWard et al. \[[@CR135]\]UnemploymentInability to work attributable to COPDPercent10.6NRNR6Productivity lossNumber work loss days per yearMean1.4NRNR*h*Helantera et al. \[[@CR65]\]UnemploymentUnemployed in 2007 for patients with dialysis or after kidney transplantPercent35NRNR6Klarenbach et al. \[[@CR64]\]UnemploymentNon-participation in labour forceOR7.94NR1.6--39.436*i*Adepoju et al. \[[@CR71]\]AbsenteeismAbsenteeism Days totalCount11,664NRNR9Absenteeism Costs totalUSD85,314NRNRProportion of total productivity losses attributable to absenteeismPercent4NRNRDays of reduced time at work as a sum of Inpatient and ambulatory visitsCount7864NRNRCosts of reduced time at work as sum of Inpatient and ambulatory visitsUSD866,744NRNRProportion of total productivity losses attributable to reduced time at workPercent3NRNRPresenteeismPresenteeism days totalCount7864NRNRPresenteeism Costs totalUSD866,744NRNRProportion of total productivity losses attributable to presenteeismPercent44NRNRProductivity lossCosts of premature mortality costs as a product of YLL and incomeUSD953,373NRNRProportion of total productivity losses attributable premature mortalityPercent49NRNRTotal productivity related lossCount20,064NRNRTotal productivity related costs lossUSD1,962,314NRNRAlavinia and Burdorf \[[@CR69]\]UnemploymentNon participation in the labor forceOR1.380NR0.990--1.9304Anesetti-Rothermel and Sambamoorthi \[[@CR10]\]Sick leaveWork days in last year lost due to illnessMean7.2501.18 (SE)NR6Bastida and Pagan \[[@CR81]\]Productivity lossUnemployment due to diabetes\
In femalesMaximum likelihood−0.0730.198NRNAUnemployment due to diabetes\
In malesMaximum likelihood−1.0470.447NRBoles et al. \[[@CR84]\]Productivity lossLost earnings per diabetic person/weekUSD67NRNR4AbsenteeismAbsenteeismOR2.285NR1.167--4.474AbsenteeismLeast squares regression coefficient3.2547.286NRPresenteeismPresenteeismOR1.271NR0.724--2.230PresenteeismLeast squares regression coefficient4.3084.369NRBradshaw et al. \[[@CR66]\]DALYsTotalCount162,877NRNR3MaleCount102,454NRNRFemaleCount101,690NRNRBurton et al. \[[@CR91]\]PresenteeismTime management (work the required no. of hours; start work on time)OR1.401NR1.14--1.735Physical work activities (e.g. repeat the same hand motions; use work equipment)OR1.415NR1.15--1.75Mental/interpersonal activities (concentration; teamwork)OR1.233NR1.02--1.50Overall output (complete required amount of work; worked to capability)OR1.158NR0.95--1.42Collins et al. \[[@CR92]\]Productivity lossImpairment score (WIS)Count17.8NR15.9, 19.67Absent hours per patient/monthCount1.3NR0.6, 1.9Work ImpairmentLinear regression coefficient−2.4NRNRAbsenceLogistic regression coefficient1.2 (not significant)NRNRDall et al. \[[@CR68]\]Productivity lossAbsenteeismUSD2470NRNR1PresenteeismUSD18,715NRNRInability to work due to diabetesUSD7276NRNRDe Backer et al. \[[@CR93]\]Sick leaveUnivariate analysis of high 1 year incidence rate of sick leave in diabetes compared to controls (25.3 %) in men (*p* value \<0.001)Percent36.9NRNR8Univariate analysis of long absences (defined as more than 7 days) in diabetes compared to controls (19.3 %) in men, (*p* value 0.002)Percent25.3NRNRUnivariate analysis for repetitive absences in diabetes compared to controls (14.5 %) in men (*p* value \<0.001)Percent21.2NRNRAdjusted analysis of high 1 year incidence rate of sick leave in diabetes compared to controls in menOR1.51NR1.22--1.88Adjusted analysis of long absences in diabetes compared to controls in menOR1.11NR0.87--1.41Adjusted analysis for repetitive absences in diabetes compared to controls in menOR1.54NR1.20--1.98Univariate analysis of high 1 year incidence rate of sick leave in diabetes compared to controls (25.1 %) in women (*p* value \<0.04)Percent33.9NRNRUnivariate analysis of long absences (defined as more than 7 days) in diabetes compared to controls (25.2 %) in women, (*p* value 0.04)Percent33.9NRNRUnivariate analysis for repetitive absences in diabetes compared to controls (24.0 %) in women (*p* value 0.002)Percent36.7NRNRAdjusted analysis of high 1 year incidence rate of sick leave in diabetes compared to controls in womenOR1.38NR0.89--2.14Adjusted analysis of long absences in diabetes compared to controls in womenOR1.45NR0.94--2.23Adjusted analysis for repetitive absences in diabetes compared to controls in menOR1.71NR1.12--2.62Etyang et al. \[[@CR6]\]DALYsRate per 100,000 PY of observationRate364NRNR5Fu et al. \[[@CR97]\]Productivity lossWork loss days due to diabetes/yearCount6.7NRNR8Bed days due to diabetes/yearCount13NRNRGenova-Maleras et al. \[[@CR4]\]DALYsRate per 1000 age standardisedRate2.2NRNR2Percentage of all causes of mortalityPercent1.9NRNRHerquelot et al. \[[@CR100]\]PresenteeismWork disability due to diabetesIncidence rate per 1000 person-years7.9NRNR7Work disability due to diabetesHR1.7NR1.0--2.9Holden et al. \[[@CR52]\]Productivity lossAbsenteeism, number of full/part days missed from work in last 4 weeksIRR1.17NR1.09--1.263Presenteeism, self-rated score of overall performance over last 4 weeksIRR0.89NR0.83--0.96Lenneman et al. \[[@CR107]\]Productivity lossProductivity impairmentUnstandardized linear regression coefficient1.816NR0.717--2.8204Klarenbach et al. \[[@CR64]\]UnemploymentNon-participation in labour forceOR2.17NR1.2--3.936Kessler et al. \[[@CR70]\]Productivity lossImpairment daysCount3.60.8NR2Any work impairmentOR1.1NR0.6--1.9Impairment daysUnstandardized linear regression coefficient−0.30.5NRLavigne et al. \[[@CR67]\]Productivity lossWork while feeling unwellPercent0.54NRNR4Variance explained work efficiency lossesPercent13NRNRHours of work lost due to diabetes, per month per personTobit regression coefficients−1NR−13.92 to −12.18Hours of absence from work due to diabetes, per month per personTobit regression coefficients1NR−1.09 to −3.45Hours of total productivity time lost per month per person due to diabetesTobit regression coefficients8NR1.42--15.03Cost of productivity time lost due to diabetesTobit regression coefficients94NR−456.8 to −645.2Mayfield et al. \[[@CR109]\]Productivity lossWork disability due to diabetesProbit model estimates1.460.228NR8Work disability due to diabetesPercent25.6NRNRWork loss days due to diabetesLinear regression0.670.318NRWork loss days due to diabetes per yearCount5.65NRNRLost earnings per diabetic person/yearUSD3099NRNRRobinson et al. \[[@CR121]\]UnemploymentRate of unemployed in those economically active for males (controls 7.8 %)Percent21.9NRNR7Rate of unemployed in those economically active for females (controls 5.1 %)Percent11.5NRNRRate of unemployed in those economically active for females (controls 7.0 % with a *p* value of \<0.001 for difference)Percent18Short et al. \[[@CR11]\]UnemploymentLimited amount of paid work possible due to illness FemaleOR1.54NR1.23--1.925Limited amount of paid work possible due to illness MaleOR2.02NR1.57--2.6Wang et al. \[[@CR134]\]AbsenteeismAnnual excess in daysMean6.46.0 (SE)NR4PresenteeismAnnual excess in daysMean7.310.3 (SE)NRAbsenteeism and Presenteeism combinedAnnual excess in daysMean16.011.0 (SE)NR*j*Torp et al. \[[@CR25]\]UnemploymentUnemployment at follow upPercent25.6NRNR9Earle et al. \[[@CR46]\]UnemploymentUnemployment at 15 monthsPercent69NRNR4*Cox PH* Cox proportional hazard regression, *DALY's* disability adjusted life years, *IRR* incidence risk ratio, *NCD* no-communicable diseases, *NA* not applicable, *NR* not reported, *OR* odds ratio, *RR* relative risk, *SD* standard deviation, *USD* United States of America dollars

Impact of stroke on productivity {#Sec12}
--------------------------------

Stroke accounted for 3.5 % of all DALYs reported in Spain (Table [2](#Tab2){ref-type="table"}b) with a rate of 3.8 per 1000 people \[[@CR4]\]. Another study from Spain reports a total count of DALYs of 418,052 with a higher number of male than for female (220,005 vs. 198,046) \[[@CR13]\]. A study from Kenya reports a rate of 166 DALYs per 100,000 person-years observed \[[@CR6]\]. In Western Australia, the average annual stroke-attributable DALY count is an estimated 26,315 for men and 30,918 for women \[[@CR14]\]. In Spain, costs after diagnosis increased over time for caregivers but declined for patients (14,732 USD in caregivers compared to 2696 USD among patients after 1 year and 15,621 USD to 1362 USD after 2 years) \[[@CR15]\]. Modeled productivity losses in South Korea were higher for a severe stroke among men (537,724 USD) than women (171,157 USD) \[[@CR16]\]. A prospective surveillance study from Tanzania report a mean costs of productivity loss to be 213 USD \[[@CR17]\]. Inconclusive evidence of the impact of stroke on RTW was reported. Estimates ranged from 26.7 to 75 % in studies reporting RTW in stroke patients after 1 year of the event \[[@CR18], [@CR19]\]. In Nigeria, 55 % returned to work at a mean of 19.5 months after stroke. A report from the United Kingdom (UK) found that 47 % were unemployed 1 year after stroke \[[@CR20]\]. Increased odds to report limited ability for paid work were found among men (3.86) and women (2.26) after stroke \[[@CR11]\].

Impact of cervical cancer on productivity {#Sec13}
-----------------------------------------

There are strong regional differences in the percentage of DALYs attributable to cervical cancer (Table [2](#Tab2){ref-type="table"}c) among women, from 1.6 % (absolute DALYs, 1061 per year) in New Zealand to 13.4 % (2516 per year) in Brazil \[[@CR21], [@CR22]\]. Cervical cancer patients in Argentina reported negative outcomes after 1 year; 45 % of patients reported reduced labor market participation, 28 % experienced work interruption and 5 % changed work \[[@CR23]\]. Compared to the general population, the relative risk (RR) for cervical cancer survivors in labor force participation was 0.77 (95 % CI 0.67--0.90), 2--3 years after diagnosis in Finland \[[@CR24]\]. In Norway however, no differences were found 5 years from diagnosis with an OR of 0.92 (0.63--1.34) \[[@CR25]\].

Impact of breast cancer on productivity {#Sec14}
---------------------------------------

Of all the DALYs attributable to cancers among women, 27.3 % (17,840 per year) in New Zealand (Table [2](#Tab2){ref-type="table"}d) and 13.4 % (6280 per year) in Brazil are attributable to breast cancer \[[@CR21], [@CR22]\]. Total mortality-related lifetime productivity loss costs in the USA were estimated to be 5.5 billion USD \[[@CR26]\]. This was differentially distributed between the two ethnic groups reported, with 71 % (or 3.9 billion USD) of the costs attributable to white women and 24 % (or 1.3 billion) attributable to black women. Differential RTW and sick absence rates are also observed comparing black and white women in the USA; the percentage of white women returning to work three months after diagnosis was 74.2 % compared to 59.6 % of black women; the proportion reporting sick leave was 25.8 % of white women compared to 40.4 % of black women \[[@CR27]\]. 1 year after primary surgery in Germany, nearly three times as many cancer survivors had left their job as compared to women in the control group. \[[@CR28]\] Various studies suggest higher unemployment among breast cancer survivors, reported by around half after 1 year, 72 % after 2 years \[[@CR29]\], 43 % after 6 years and 18 % after 9 years \[[@CR27], [@CR28], [@CR30]--[@CR32]\]. In contrast, in a study assessing unemployment among the spouses of breast cancer patients, no differences were found \[[@CR33]\]. Differences between countries in average time to RTW were also found, from 11.4 months in the Netherlands \[[@CR34]\] and 7.4 months in Canada \[[@CR35]\] to only 3 months in Sweden \[[@CR36]\]. Percentage of RTW after 1 year ranged from 54.3 % in a cross-sectional study from France to 82 % in a prospective study from the USA \[[@CR37], [@CR38]\].

Impact of cancer on productivity {#Sec15}
--------------------------------

In New Zealand, of all the DALYs attributable to cancers, 12.9 % (8431 per year) among women and 13.5 % (8316 per year) among men are attributable to colon cancer (Table [2](#Tab2){ref-type="table"}e) \[[@CR22]\]. In Brazil, these proportions are 9.3 % among women and 7.5 % among men \[[@CR21]\]. In Spain, 2.1 % of DALY's overall are attributable to colon cancer \[[@CR4]\]. In Iran the total burden of colorectal cancer in 2008 was 52,534 DALYs and higher for men than for women \[[@CR39]\]. In the USA, annual productivity losses were calculated to be 20.9 billion USD \[[@CR40]\], while costs due to absenteeism after 1 year of diagnosis was 4245 USD per patient compared to the general population \[[@CR41]\]. Although the DALY and dollar costs of colon cancer are undoubtedly large, the evidence for micro-level labor market indicators including risk and proportions of RTW, sickness absence and employment following diagnosis and treatment is however inconclusive \[[@CR25], [@CR42]--[@CR49]\]. In New Zealand, of all cancer-attributable DALYs, 14.4 % (9334 per year) among women and 15.9 % (9806 per year) among men are attributable to lung cancer (Table [2](#Tab2){ref-type="table"}f) \[[@CR22]\]. In Brazil, lung cancer results in an estimated 10,832 DALYs per year, 9.8 % of all cancer-related DALYs among women and 24.5 % among men \[[@CR21]\]. In Spain, 3.4 % of all DALYs are attributable to lung cancer \[[@CR4]\]. Most of the first year of disease (275 days) is spent in sickness absence in Sweden \[[@CR36]\] and between 33 and 79 % of lung cancer patients in the USA were unemployed 15 months after diagnosis \[[@CR43], [@CR46]\]. Average time to re-enter the labor market was 484 days for full-time work and 377 for part-time work in the Netherlands \[[@CR50]\]. The odds of re-entry into the labor market were significantly lower for lung cancer than the general population \[[@CR24], [@CR25], [@CR51]\].

Impact of COPD on productivity {#Sec16}
------------------------------

COPD patients have a higher chance of working fewer hours, of absenteeism and of poorer work performance (presenteeism) (Table [2](#Tab2){ref-type="table"}g). \[[@CR11], [@CR52], [@CR53]\]. A COPD patient loses around 8.5 workdays per year due to disease \[[@CR10], [@CR54]\]. Between 39 and 50 % of people stopped working due to the onset of COPD in the Netherlands \[[@CR55], [@CR56]\]. COPD-related productivity losses cost the US economy around 88 million USD or around 482,966 working days per year \[[@CR57]\]. Modeled annual costs of COPD, estimated at 1.47 billion USD \[[@CR58]\], are higher in Japan than the USA. The productivity loss costs PP/PY were somewhat comparable between Germany, Sweden and the Netherlands (566, 749 and938 USD respectively) \[[@CR57], [@CR59], [@CR60]\], but differed four-fold to estimated costs in Denmark (2816--3819 USD) \[[@CR61], [@CR62]\] and more than tenfold to what was estimated (9815 USD) in the USA \[[@CR63]\]. In the USA, 8.5 work days are lost PP/PY on average \[[@CR10]\], while COPD patients take an estimated 8.6 days of sickness absence in the Netherlands during a 2 year follow-up period \[[@CR54]\]. Also in the Netherlands, 39 % of COPD patients left the labor force due to disease onset \[[@CR55]\].

Impact of chronic kidney disease on productivity {#Sec17}
------------------------------------------------

Only two studies (Table [2](#Tab2){ref-type="table"} h) examined the impact of CKD on productivity. One found that renal dysfunction was independently associated with labor force non-participation, with an odds ratio of 7.94 (95 % confidence interval, 1.60--39.43) \[[@CR64]\]. The second study, evaluating labor market participation in CKD patients specifically after dialysis or transplantation, found that 35 % of these CKD patients were unemployed \[[@CR65]\].

Impact of diabetes mellitus on productivity {#Sec18}
-------------------------------------------

In Spain, nearly 2 % of all mortality-related DALYs are attributable to DM \[[@CR4]\]. In South Africa, 162,877 DALYs annually are attributable to DM (Table [2](#Tab2){ref-type="table"}i) \[[@CR4], [@CR66]\]. A study from Kenya reports a rate of 364 DALYs per 100,000 observed person-years \[[@CR6]\]. An estimated 7.2 days are lost PP/PY due to DM in the USA \[[@CR10]\] and DM patients have an increased risk of absenteeism, presenteeism and inability to work \[[@CR4], [@CR10], [@CR11], [@CR52], [@CR64], [@CR67]--[@CR69]\]. Productivity days lost per year due to diabetes ranged from 3.6 to 7.3 \[[@CR10], [@CR70]\]. In the USA, proportion of productivity loss was large due to premature mortality (49 %) and presenteeism (44 %) compared to absenteeisim (4 %) and total productivity related costs were estimated to be 1,962,314 USD \[[@CR71]\]. The odds of non-participation of the labor force for diabetes patients compared to the general population were slightly higher with borderline significance in the EU, an OR of 1.38 (95 % CI 0.99--1.93) \[[@CR69]\].

Discussion {#Sec19}
==========

This systematic review identified 126 studies investigating the impact of NCDs on productivity. Most studies (96 %) were from the Western world (North America, Europe or Asia Pacific), with limited evidence available from Brazil, South Africa, Kenya, Tanzania, Iran, Japan, South Korea and Argentina. Macro-economic productivity losses were measured in percentage and absolute numbers of DALYs and annual productivity loss costs (in USD). Studies also estimated productivity losses using labor market indicators including unemployment, RTW, absenteeism, presenteeism, sickness absence and loss in working hours. There is a clear scarcity in literature concerning the effect of CKD on productivity, with only two studies both reporting a substantial impact on productivity \[[@CR64], [@CR65]\].

Diversity in the macroeconomic measures and outcomes {#Sec20}
----------------------------------------------------

There were considerable global differences in the NCD-attributable DALY burden, especially the differential impact of each NCD comparing high-income countries (HIC) and low- and middle-income countries (LMIC). Lung and colon cancer account for nearly 30 % of all cancer-attributable DALYs in men in New Zealand whereas in Brazil, lung cancer alone accounts for nearly 25 %. Among women in HIC, breast cancer seems to impose a large productivity burden whereas cervical cancer impacts more dramatically in LMIC \[[@CR4], [@CR21], [@CR22]\]. Although DALYs are a reliable measure and capture both years of life lost and years spent in ill-health, we found inconsistent application in the identified studies; some estimated proportions within specific disease groups or of the overall DALY burden in a country; others estimated absolute DALY numbers.

Diversity in the macro-economic impact of the cardiopulmonary diseases {#Sec21}
----------------------------------------------------------------------

Absolute costs (measured in USD) were estimated for COPD, CHD, and stroke events \[[@CR7], [@CR9], [@CR15], [@CR57], [@CR58], [@CR71]\]. These studies mainly came from HIC, although two studies, one from Kenya and one from Tanzania, were also retrieved. In Australia, absenteeism and lower employment due to CHD cost 13.2 billion USD annually, as well as an additional 23 million USD in mortality-related costs \[[@CR9]\]. Evidence suggests that COPD costs around 88 million USD or nearly 500,000 working days per year in the US compared to 1.47 billion (modeled) in Japan. While annual COPD-related productivity costs were comparable in Germany, Sweden and the Netherlands (between 566 and 938 USD), costs differed fourfold (2816--3819 USD) in Denmark, tenfold (9815 USD) in the USA \[[@CR57], [@CR59]--[@CR63]\]. In the USA, nearly half of the annual 1.96 m USD productivity losses due to DM are attributable to mortality, with 44 % attributable to presenteeism and just 4 % to absenteeism In South Korea, modeled productivity losses for a stroke were 68 % higher among men compared to women \[[@CR16]\]. Around half of all stroke survivors in unemployed after 1 year \[[@CR20]\]. In Tanzania, productivity losses after 6 months following stroke were 213 USD on average although these losses were most acutely experienced by those in higher skill roles \[[@CR17]\]. Interestingly, indirect productivity losses were higher among caregivers than stroke patients themselves and costs increased for caregivers but declined for patients after 1 and 2 years following a stroke in Spain. COPD patients experience reduced working hours, unemployment, absenteeism and presenteeism \[[@CR10], [@CR11], [@CR52]--[@CR56]\]. DM patients also have an increased risk of reduced labor market participation \[[@CR10], [@CR11], [@CR52], [@CR64]\]. By contrast, other than for absenteeism \[[@CR10]\] the evidence for the risk of reduced labor market participation due to CVD is inconclusive. In Kenya, 68/100,000 person year observed are attributable to CVD compared to 166/100,000 for stroke and 364/100,000 for DM \[[@CR6]\]. Although evidence is limited, the higher productivity impact associated with diseases with a large morbidity was perhaps to be expected; chronic diseases such as COPD and DM affect people during their productive years and cannot really be 'cured', only managed. The extent to which employers or societies support and enable NCD populations to remain members of the productive workforce will also differentially distribute the impact. The extent to which secondary or tertiary prevention is possible will also affect productivity estimates, specifically so for labor market indicators such as RTW, change in work status or unemployment.

Diversity in the macroeconomic impact of cancer {#Sec22}
-----------------------------------------------

Lung cancer survival is associated with reduced labor market participation through sickness absence, extended RTW \[[@CR36], [@CR50]\] and unemployment \[[@CR25], [@CR43], [@CR46]\]. Total mortality-related lifetime productivity loss due to breast cancer were an estimated 5.5 billion USD in the USA \[[@CR26]\] and annual productivity losses due to colon cancer costs the US economy 20.9 billion USD \[[@CR40]\].We found inconclusive evidence of risk of reduced labor market participation (RTW, sickness absence and unemployment) following colon cancer diagnosis and treatment \[[@CR25], [@CR42]--[@CR46], [@CR48]\]. The evidence for breast cancer-related labor market drop-out shows higher unemployment among survivors 1, 2, 6 and 9 years after diagnosis \[[@CR29]--[@CR32]\]. Evidence from the USA also suggests ethnicity-patterned differences in sick leave and unemployment \[[@CR27]\]. Along with possible socio-economic differences associated with these outcomes \[[@CR72]\], pathophysiological differences may also play a role. African-American women have lower incidence of breast cancer but higher mortality and are also diagnosed in later stages and with more aggressive types of tumors \[[@CR73]\]. However, we are cautious in over interpretation of this finding as few studies included ethnicity. Geographic differences in average months to RTW were observed from 11.4 in the Netherlands \[[@CR34]\] to 7.4 in Canada \[[@CR35]\] to just three months in Sweden \[[@CR36]\].

Although evidence is limited, the higher productivity impact associated with diseases with a large morbidity was perhaps to be expected; chronic diseases such as COPD and DM affect people during their productive years and cannot really be 'cured', only managed. It is surprising that half of all productivity losses in the USA attributable to DM are due to mortality rather than absenteeism and presenteeism. The extent to which employers or societies support and enable NCD populations to remain members of the productive workforce will also differentially distribute the impact both within societies but also comparing more affluent to less affluent countries. The extent to which secondary or tertiary prevention is possible will also affect productivity estimates, specifically so for labor market indicators such as RTW, change in work status or unemployment.

Comparison with the previous work {#Sec23}
---------------------------------

Findings of this systematic review generally concur with and further extend the previous reviews. This study is a comprehensive systematic review tackling work-related burden of six major NCDs using a global perspective and without language limitation. Two reviewers included and assessed the studies and references of the included studies were tracked for any missing evidence. These approaches ensured that we included most of the relevant articles in our review. Similar to previous reviews, we found that, due to a great amount of variation in the studies included, comparability and pooling the studies were not possible. Most of the previous reviews were performed non-systematically and previous systematic reviews have included studies only in English. Previous studies were mainly focused on the impact of cancers \[[@CR74]--[@CR78]\] on work-related outcomes (mainly RTW) and often included a mix of cancers without specifying the type of cancer. Van Muijen and colleagues \[[@CR78]\] reviewed only cohort studies of cancer-related work outcomes and were focused on English language. Steiner and colleagues \[[@CR76]\] reviewed English publications published up until 2003, Breton and colleagues were focused only on diabetes and Krisch and colleagues focused on COPD in Germany \[[@CR79]\].

Strengths and limitations of the current work {#Sec24}
---------------------------------------------

In this systematic review we evaluated the literature concerning the impact on productivity of six top NCDs. These six were selected based on their dominance in the global burden of disease and together make a huge contribution to mortality and morbidity worldwide. Several important issues are out of scope for this work but do merit future research. First, we did not look into the underlying mechanisms of what forces people with NCDs in and out of the labor force, specifically in terms of co-morbidities (certain NCDs cluster in the same populations) and financial/social means available at an individual and collective level. How these mechanisms interact will also be different according to the level of economic and social development. For example, children in LMIC are more likely to be forced into the labor market due to the onset of NCDs in parents compared to children in HIC and the productive output of this child cannot replace the loss due to drop out by the parents. These related topics should be addressed separately to better understand how to modify and target these outcomes more specifically. Second, we observed wide heterogeneity in all domains within the studies selected, including study design, methods and sources used to measure productivity, adjustment for confounders and analyses. Third, no identified studies quantified the differential productivity impact by national economic development and labor market structure across countries. How these inter-country macro-economic differences might mitigate or magnify productivity losses associated with NCDs is worth further exploration. Fourth, we identified a crucial gap of relevant information from LMICs---limiting the relevance of our review most acutely in these settings. This lack of evidence could reflect differences in disease burden, in research capacity, in welfare systems and in epidemiological surveillance. The burden of NCDs is growing rapidly in LMIC; countries that often lack capacity in these key areas of support, prevention and knowledge generation. Further evaluation, therefore, of the macro-economic impact in the LMIC countries is urgently needed. Also, many NCDs affect people cumulatively over time; people may suffer DM, may experience absenteeism/presenteeism as a result, may reduce work as DM worsens and may finally drop out of the workforce due a stroke or CHD, which is related to the DM. Given NCDs are shifting more and more into chronic conditions, as our understanding of treatment and natural history improve, it would be of great interest to investigate the effects over the life course rather than using short time horizons such as a year. This is no mean feat, but could be crucial for developing a better understanding of the economic impact of NCDs on a regional, national and international level. Also out of scope for this review but of interest for future work are the productivity-related impact of behavioural risk factors that contribute to the development of NCDs.

Conclusions {#Sec25}
===========

In summary, available studies indicate that the six main NCDs generate a large impact on macro-economic productivity in the WHO regions. However, this evidence is heterogeneous, of varying quality and not evenly geographically distributed. Data from LMI countries in economic and epidemiological transition are virtually absent. Further work to reliably quantify the absolute global impact of NCDs on macro-economic productivity and DALYs is urgently required.
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Appendix 1: Search strategy up to 6th of November 2014 {#Sec26}
======================================================

('non communicable disease'/de OR 'ischemic heart disease'/exp OR 'cerebrovascular accident'/exp OR 'chronic obstructive lung disease'/de OR 'lung cancer'/exp OR 'colon cancer'/exp OR 'breast cancer'/exp OR 'chronic kidney disease'/de OR 'non insulin dependent diabetes mellitus'/de OR 'uterine cervix cancer'/exp OR ('non communicable' OR noncommunicable OR ((heart OR cardiac OR cardial OR cardiopath\* OR cardiomyopath\* OR coronar\* OR myocard\*) NEAR/3 (ischem\* OR ischaem\* OR anoxia OR hypoxia)) OR (coronary NEAR/3 (insufficien\* OR occlus\* OR disease\* OR acute OR atherosclero\* OR arteriosclero\* OR sclero\* OR cardiosclero\* OR constrict\* OR vasoconstrict\* OR obstruct\* OR stenosis\* OR thrombo\*)) OR angina\* OR ((heart OR myocard\* OR cardiac OR cadial) NEAR/3 infarct\*) OR ((cerebrovascul\* OR brain OR 'cerebral vascular' OR 'cerebro vascular') NEAR/3 (accident\* OR lesion\* OR attack OR ischem\* OR ischaem\* OR insult\* OR insuffucien\* OR arrest\* OR apoplex\*)) OR cva OR stroke OR (chronic AND (obstruct\* NEAR/3 (lung\* OR pulmonar\* OR airway\* OR bronch\* OR respirat\*))) OR ((lung\* OR pulmonar\* OR colon\* OR colorect\* OR breast\* OR mamma\*) NEAR/3 (neoplas\* OR cancer\* OR carcino\* OR adenocarcino\* OR metasta\* OR sarcom\*)) OR (chronic NEAR/3 (kidney\* OR nephropathy\* OR renal)) OR (('adult onset' OR 'type 2' OR 'type ii' OR 'non-insulin dependent' OR 'noninsulin dependent' OR 'insulin independent') NEAR/3 diabet\*) OR ((cervix OR cervical) NEAR/3 (cancer\* OR neoplas\* OR tumo\* OR carcinom\* OR malign\*))):ab,ti) AND (adult/exp) AND ('randomized controlled trial'/exp OR 'cohort analysis'/de OR 'case control study'/exp OR 'cross-sectional study'/de OR 'systematic review'/de OR 'meta analysis'/de OR ecology/exp OR 'ecosystem health'/exp OR 'ecosystem monitoring'/exp OR model/exp OR ((random\* NEAR/3 (trial\* OR control\*)) OR rct\* OR cohort\* OR 'case control' OR 'cross-sectional' OR (systematic\* NEAR/3 review\*) OR metaanaly\* OR (meta NEXT/1 analy\*) OR ecolog\* OR ecosystem\* OR model\*):ab,ti) NOT (\[animals\]/lim NOT \[humans\]/lim) NOT (\[Conference Abstract\]/lim OR \[Conference Paper\]/lim OR \[Letter\]/lim OR \[Note\]/lim OR \[Conference Review\]/lim OR \[Editorial\]/lim OR \[Erratum\]/lim).

AND (productivity/de OR absenteeism/de OR 'job performance'/de OR 'return to work'/de OR 'work capacity'/de OR 'working time'/de OR 'medical leave'/de OR workload/de OR retirement/de OR employment/exp OR unemployment/de OR (productivit\* OR unproductivit\* OR absenteeis\* OR presenteeis\* OR ((job OR work\* OR profession\* OR occupation\* OR labour) NEAR/3 (perform\* OR efficien\* OR return\* OR back OR capacit\* OR abilit\* OR disabilit\* OR unab\* OR limit\* OR impair\* OR loss OR losing OR restrict\* OR reduct\* OR input\*)) OR (work\* NEXT/1 (time OR week\* OR day\* OR load\*)) OR workweek\* OR workday\* OR ((medical OR sick) NEXT/1 leave) OR workload\* OR 'time off work' OR retire\* OR employment\* OR employed\* OR unemploy\* OR daly OR ('disability adjusted' NEXT/2 year\*)):ab,ti).

Appendix 2: Newcastle--ottawa quality assessment scale {#Sec27}
======================================================

Cross-sectional and descriptive studies {#Sec28}
---------------------------------------

*Note*: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

SelectionIs definition of NCDs adequate?Yes, according to a clear and widely used definition**\***Yes, e.g. record linkage or based on self-reportsNo descriptionRepresentativeness of the casesConsecutive or obviously representative series of cases**\***Excluded cases are random**\***No description of the excluded cases or potential for selection biases or not statedComparison with a reference groupThe results are compared with a reference from community or with the status of the cases prior to the disease**\***The results are compared with the results from other patientsNo description/no comparison availableDefinition of referenceIndividuals with no NCD or sample from general population or the same individuals before NCD suffering**\***Non community comparator is describedNo description of source

Comparability {#Sec29}
-------------

Comparability of the results on the basis of the design or analysisThe results are described in age and sex sub groups (sex is not applicable for female diseases)**\***The results are additionally *adjusted for/described in* different socioeconomic factors or disease related confounders**\***

Exposure (costs, productivity, households) {#Sec30}
------------------------------------------

Ascertainment of exposureSecure record (e.g. surgical records, hospital records, and administrative records, national...)**\***Structured interview where blind to case/control status**\***Interview not blinded to case/control statusWritten self-report or medical record onlyNo descriptionSame method of ascertainment for NCDs and comparatorsYes**\***NoNo comparator group existNon-response rateAll participants included or same rate for both groups or respondents and non-respondents have the same characteristics**\***Non respondents describedRate different and no designationResponse rate not described
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